Aardvark Therapeutics (AARD) Competitors $13.82 +0.35 (+2.60%) As of 09:44 AM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock AARD vs. SYRE, ZYME, AMPH, SANA, RCUS, PROK, VERV, LENZ, BGM, and ORICShould you be buying Aardvark Therapeutics stock or one of its competitors? The main competitors of Aardvark Therapeutics include Spyre Therapeutics (SYRE), Zymeworks (ZYME), Amphastar Pharmaceuticals (AMPH), Sana Biotechnology (SANA), Arcus Biosciences (RCUS), ProKidney (PROK), Verve Therapeutics (VERV), LENZ Therapeutics (LENZ), BGM Group (BGM), and Oric Pharmaceuticals (ORIC). These companies are all part of the "pharmaceutical products" industry. Aardvark Therapeutics vs. Its Competitors Spyre Therapeutics Zymeworks Amphastar Pharmaceuticals Sana Biotechnology Arcus Biosciences ProKidney Verve Therapeutics LENZ Therapeutics BGM Group Oric Pharmaceuticals Spyre Therapeutics (NASDAQ:SYRE) and Aardvark Therapeutics (NASDAQ:AARD) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, dividends, valuation, risk, media sentiment, profitability and institutional ownership. Do analysts recommend SYRE or AARD? Spyre Therapeutics presently has a consensus target price of $53.40, indicating a potential upside of 211.13%. Aardvark Therapeutics has a consensus target price of $33.00, indicating a potential upside of 138.78%. Given Spyre Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe Spyre Therapeutics is more favorable than Aardvark Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Spyre Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 2 Strong Buy rating(s) 3.29Aardvark Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do institutionals & insiders believe in SYRE or AARD? 80.4% of Spyre Therapeutics shares are owned by institutional investors. 15.4% of Spyre Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Is SYRE or AARD more profitable? Aardvark Therapeutics' return on equity of 0.00% beat Spyre Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Spyre TherapeuticsN/A -77.46% -41.06% Aardvark Therapeutics N/A N/A N/A Does the media favor SYRE or AARD? In the previous week, Spyre Therapeutics and Spyre Therapeutics both had 1 articles in the media. Spyre Therapeutics' average media sentiment score of 1.87 beat Aardvark Therapeutics' score of 0.93 indicating that Spyre Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Spyre Therapeutics Very Positive Aardvark Therapeutics Positive Which has better earnings and valuation, SYRE or AARD? Aardvark Therapeutics has lower revenue, but higher earnings than Spyre Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSpyre Therapeutics$890K1,162.46-$208.02M-$3.77-4.55Aardvark TherapeuticsN/AN/A-$20.59MN/AN/A SummarySpyre Therapeutics beats Aardvark Therapeutics on 7 of the 10 factors compared between the two stocks. Get Aardvark Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AARD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding AARD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AARD vs. The Competition Export to ExcelMetricAardvark TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$299.89M$3.04B$5.71B$9.50BDividend YieldN/A2.40%4.60%3.99%P/E RatioN/A20.8727.8819.97Price / SalesN/A324.50452.35101.58Price / CashN/A43.2336.5558.97Price / BookN/A8.328.635.89Net Income-$20.59M-$55.19M$3.24B$258.50M7 Day Performance18.93%5.61%3.90%2.07%1 Month Performance-10.14%17.39%10.47%12.39%1 Year PerformanceN/A4.47%34.29%19.25% Aardvark Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AARDAardvark TherapeuticsN/A$13.82+2.6%$33.00+138.8%N/A$299.89MN/A0.0018Gap DownSYRESpyre Therapeutics2.465 of 5 stars$16.99+0.6%$53.40+214.3%-42.7%$1.02B$890K-4.5073Positive NewsZYMEZymeworks2.9581 of 5 stars$14.61+0.9%$21.00+43.7%+34.7%$1.02B$93.38M-9.74460Upcoming EarningsAMPHAmphastar Pharmaceuticals4.4742 of 5 stars$21.57-0.6%$32.33+49.9%-45.4%$1.02B$731.97M7.822,028SANASana Biotechnology3.2063 of 5 stars$4.52+1.6%$9.17+102.8%-16.2%$1.02BN/A-5.12380RCUSArcus Biosciences1.5778 of 5 stars$9.56+1.4%$21.29+122.8%-32.2%$1.01B$258M-2.28500PROKProKidney3.4298 of 5 stars$3.40-3.5%$6.25+84.0%+55.2%$988.16M$80K-5.633VERVVerve Therapeutics2.9104 of 5 stars$10.96+0.0%$14.57+33.0%+57.2%$976.53M$32.33M-5.19110News CoverageLENZLENZ Therapeutics1.3176 of 5 stars$34.55-0.1%$46.60+34.9%+41.9%$972.58MN/A-19.52110Gap UpBGMBGM GroupN/A$10.01+3.7%N/AN/A$971.71M$25.10M0.00298ORICOric Pharmaceuticals4.2966 of 5 stars$11.17+0.3%$18.57+66.3%+8.8%$950.63MN/A-5.9780 Related Companies and Tools Related Companies SYRE Alternatives ZYME Alternatives AMPH Alternatives SANA Alternatives RCUS Alternatives PROK Alternatives VERV Alternatives LENZ Alternatives BGM Alternatives ORIC Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AARD) was last updated on 7/25/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aardvark Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aardvark Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free AARD Stock Alerts